ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
January 30, 2024 07:00 ET | ITM Isotope Technologies Munich SE
GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9),...
Erasmus MC
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
January 24, 2024 09:10 ET | AIM ImmunoTech Inc.
OCALA, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has received authorization from the Erasmus Medical Center...
1ProLynx LOGO.png
ProLynx announces a publication proposing that a long-acting prodrug of SN-38 could be effective in treating Sacituzumab Govitecan-Resistant Tumors
January 24, 2024 09:00 ET | ProLynx LLC
SAN FRANCISCO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc., a biotech company with a unique technology for tunable half-life extension of drugs, announced publication of a paper entitled “Could...
image1 (1).png
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
January 24, 2024 08:30 ET | Evaxion Biotech
Tailored Vaccines: With the AI-Immunology™ enabled discovery of these novel types of cancer vaccine targets, designing personalized and precision vaccine solutions becomes feasible and highly...
Unnatural Products, Inc. Enters Research Collaboration with Merck
January 23, 2024 09:00 ET | Unnatural Products
Santa Cruz, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech company pairing AI with chemistry to enable the next generation of molecularly targeted therapeutics,...
website-logo (2).png
Circulating Tumor Cells Market Projected to Exceed US$ 81.6 Bn by 2033 at CAGR of 19.11% | Report
January 23, 2024 00:35 ET |
New York, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The circulating tumor cells market was valued at USD 14.84 billion in 2023 with significant growth and is projected to reach USD 81.6 billion by 2033 with...
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
January 22, 2024 08:55 ET | AIM ImmunoTech Inc.
OCALA, Fla., Jan. 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first subject has been enrolled at Erasmus Medical Center...
NOVARTIS logo.jpg
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
January 19, 2024 10:00 ET | Novartis Pharma AG
In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2...
Transparency Market Research
Stem Cell Assays Market Size & Share to Surpass USD 8.5 billion by 2033 | Analysis by Transparency Market Research
January 18, 2024 09:30 ET | Transparency Market Research
Wilmington, Delaware, United States, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global stem cell assays market is estimated to flourish at a CAGR of 16.5% from 2023 to...
Elevar Logo for Common Use.png
Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study at 2024 ASCO Gastrointestinal Cancers Symposium
January 18, 2024 08:45 ET | Elevar Therapeutics
A post hoc analysis found the efficacy of camrelizumab plus rivoceranib was superior to sorafenib regardless of baseline liver function as measured by both albumin-bilirubin grade and Child-Pugh...